Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin

NCT03510000 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Type1diabetes

Interventions

DRUG: Empagliflozin 25mg
DEVICE: Single hormone artificial pancreas
BEHAVIORAL: Meal strategies

Sponsor

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Collaborators

[object Object]
[object Object]
[object Object]